Neurocrine Biosciences Unveils Promising One-Year Phase 3 Results on Glucocorticoid Treatment Improvements at 2025 ENDO Meeting Neurocrine Biosciences showcased significant one-year data at the 2025 Endocrine Society Meeting, highlighting weight management success in CAH patients treated with CRENESSITY.

Neurocrine Biosciences Unveils Promising One-Year Phase 3 Results on Glucocorticoid Treatment Improvements at 2025 ENDO Meeting #United_States #San_Francisco #Crenessity #Neurocrine_Biosciences #CAHtalyst

New Exploratory Findings on CRENESSITY™ from Neurocrine Biosciences for Pediatric CAH Patients Neurocrine Biosciences reveals significant findings from the Phase 3 CAHtalyst™ Pediatric study, showing CRENESSITY™ improves outcomes for CAH patients.

New Exploratory Findings on CRENESSITY™ from Neurocrine Biosciences for Pediatric CAH Patients #USA #San_Diego #Crenessity #Neurocrine_Biosciences #CAHtalyst